Article
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
Nature communications - 28 Oct 2023
Ptashkin Ryan N, Ewalt Mark D, Jayakumaran Gowtham, Kiecka Iwona, Bowman Anita S, Yao JinJuan, Casanova Jacklyn, Lin Yun-Te David, Petrova-Drus Kseniya, Mohanty Abhinita S, Bacares Ruben, Benhamida Jamal, Rana Satshil, Razumova Anna, Vanderbilt Chad, Balakrishnan Rema Anoop, Rijo Ivelise, Son-Garcia Julie, de Bruijn Ino, Zhu Menglei, Lachhander Sean, Wang Wei, Haque Mohammad S, Seshan Venkatraman E, Wang Jiajing, Liu Ying, Nafa Khedoudja, Borsu Laetitia, Zhang Yanming, Aypar Umut, Suehnholz Sarah P, Chakravarty Debyani, Park Jae H, Abdel-Wahab Omar, Mato Anthony R, Xiao Wenbin, Roshal Mikhail, Yabe Mariko, Batlevi Connie Lee, Giralt Sergio, Salles Gilles, Rampal Raajit, Tallman Martin, Stein Eytan M, Younes Anas, Levine Ross L, Perales Miguel-Angel, van den Brink Marcel R M, Dogan Ahmet, Ladanyi Marc, Berger Michael F, Brannon A Rose, Benayed Ryma, Zehir Ahmet, Arcila Maria E
Abstract excerpt
Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic. Tumor only sequencing assays are limited in their ability to identify definitive somatic variants, which can lead to ambiguity in clinical reporting and patient management. Here, we describe...
Topics
Join the communities discussing this publication.